Phase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
Condition: Antiphospholipid Syndrome (APS) · Bullous Pemphigoid (BP) · Behçet's Syndrome (BS) · Sponsor: Chugai Pharmaceutical
About this study
This is a long-term extension trial of RAY121 in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (62)
| Royal Prince Alfred Hospital | Camperdown, New South Wales, Australia | — |
| Westmead Hospital | Sydney, New South Wales, Australia | — |
| Campbelltown Public Hospital | Sydney, New South Wales, Australia | — |
| The Alfred Hospital | Melbourne, Victoria, Australia | — |
| Box Hill Hospital | Melbourne, Victoria, Australia | — |
| AKH - Medizinische Universitaet Wien, Abteilung fuer Klinische Pharmakologie | Vienna, Austria | — |
| Diagnostic Consultation Center CONVEX EOOD | Sofia, Sofia City Province, Bulgaria | — |
| "SHATHD" EAD Sofia | Sofia, Sofia City Province, Bulgaria | — |
| UMHAT "Prof. Dr. St. Kirkovich", AD | Stara Zagora, Stara Zagora Province, Bulgaria | — |
| DiIEX Recherche Sherbrooke, Inc | Sherbrooke, Quebec, Canada | — |
| Clinical Hospital Center "Sestre Milosrdnice" | Zagreb, City of Zagreb, Croatia | — |
| University hospital centre Zagreb | Zagreb, City of Zagreb, Croatia | — |
+ 50 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06723106